<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02164994</url>
  </required_header>
  <id_info>
    <org_study_id>1402</org_study_id>
    <nct_id>NCT02164994</nct_id>
  </id_info>
  <brief_title>Prospective Evaluation of the Long-term Effectiveness of the Femtosecond Laser-assisted Arcuate Incisions</brief_title>
  <official_title>Prospective Evaluation of the Long-term (18 Months) Effectiveness of the Femtosecond Laser-assisted Arcuate Incisions Following Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technolas Perfect Vision GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technolas Perfect Vision GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study is an open, controlled, prospective, single center, single-surgeon,&#xD;
      post-market-clinical-follow-up study to evaluate the long-term (18 months) effectiveness of&#xD;
      the femtolaser-assisted astigmatic keratotomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this prospective post-market-clinical-follow-up study is to address the&#xD;
      long-term effectiveness of arcuate incisions, in eyes after VICTUS femtosecond laser-assisted&#xD;
      astigmatic keratotomy.&#xD;
&#xD;
      This study will be conducted at Gemini eye clinic in Zlin, Czech Republic by Dr. Pavel&#xD;
      Stodulka who will examine up to 100 eyes who previously received VICTUS femtolaser-assisted&#xD;
      arcuate incisions treatment.&#xD;
&#xD;
      Patients will be recruited according to the study inclusion/exclusion criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative keratometric cylinder</measure>
    <time_frame>18 months after the VICTUS femtosecond laser-assisted arcuate incisions.</time_frame>
    <description>Postoperative Astigmatism (keratometry) ≤ 1.0 D in 60% of eyes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative Manifest Cylinder</measure>
    <time_frame>19 months after VICTUS femtosecond laser-assisted arcuate incisions treatment.</time_frame>
    <description>Postoperative Manifest Astigmatism (manifest refraction) ≤ 1.0 D in 60% of eyes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Objective Cylinder</measure>
    <time_frame>18 months after VICTUS femtosecond laser-assisted arcuate incisions treatment.</time_frame>
    <description>Postoperative Objective Astigmatism (manifest refraction) ≤ 1.0 D in 60% of eyes</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Astigmatism</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Only the patients who were previously treated with VICTUS™ femtosecond laser-assisted&#xD;
        arcuate incisions and successfully pass the eligibility criteria are eligible for this&#xD;
        follow-up extension study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clear corneal media&#xD;
&#xD;
          -  Patients must be at least 40 years of age&#xD;
&#xD;
          -  VICTUS™ femtosecond laser-assisted arcuate incisions surgery&#xD;
&#xD;
          -  Preoperative Keratometric astigmatism: ≥ 1.0D and ≤ 3D&#xD;
&#xD;
          -  Patients must have read, understood the Patient Information and signed the informed&#xD;
             consent form&#xD;
&#xD;
          -  Patients are willing and able to return for follow-up examinations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Corneal disease or pathology, such as corneal scaring&#xD;
&#xD;
          -  Subjects with a poorly dilating pupil or other defect of the pupil that prevents the&#xD;
             iris from adequate retraction peripherally&#xD;
&#xD;
          -  Lens/zonular instability such as, but not restricted to, Marfan's Syndrome,&#xD;
             Pseudoexfoliation Syndrome, etc.&#xD;
&#xD;
          -  Manifest Glaucoma&#xD;
&#xD;
          -  Known sensitivity to planned concomitant medications&#xD;
&#xD;
          -  Patients regularly taking medicines that could influence the result of the treatment&#xD;
             respectively the vision&#xD;
&#xD;
          -  Patients with disorders of the ocular muscle, such as nystagmus or strabismus&#xD;
&#xD;
          -  Patients with keratoconus, keratectasia or other irregular cornea changes&#xD;
&#xD;
          -  Patients with connective tissue weakness&#xD;
&#xD;
          -  Subjects who are immune compromised or carrying diagnosis of connective tissue&#xD;
             disease, clinically significant atopic disease, insulin dependent diabetes mellitus,&#xD;
             autoimmune diseases, ocular herpes zoster or simplex, endocrine diseases, lupus,&#xD;
             rheumatoid arthritis, collagenosis and other acute or chronic illnesses that will&#xD;
             increase the risk to the subject or confound the outcomes of this study.&#xD;
&#xD;
          -  Abnormal examination results from slit lamp, fundus examination or IOLMaster; age&#xD;
             related changes are acceptable&#xD;
&#xD;
          -  Patients with eye diseases which decreases the visual acuity such as macular&#xD;
             degeneration, macular edema, proliferative diabetic retinopathy&#xD;
&#xD;
          -  Abnormal examination results from topography, age related changes are acceptable&#xD;
&#xD;
          -  Patients who are pregnant or nursing&#xD;
&#xD;
          -  Patients with concentration disorders, epilepsy and other complicating diseases&#xD;
&#xD;
          -  Patients who are participating in another clinical study 30 days before&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pavel Stodulka, Dr. med, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gemini clinic, Zlin Pavel Stodulka, Dr. med Study Principal Investigator Gemini eye clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pavel Stodulka, Dr. med, PhD</last_name>
    <phone>+420734575158</phone>
    <email>barinkova@gemini.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gemini Eye Clinic</name>
      <address>
        <city>Zlin</city>
        <zip>76001</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Stodulka, Dr. med, PhD</last_name>
      <phone>+420734575158</phone>
      <email>barinkova@gemini.cz</email>
    </contact>
    <contact_backup>
      <last_name>Eliška Bařinková</last_name>
      <phone>+420734575158</phone>
      <email>barinkova@gemini.cz</email>
    </contact_backup>
    <investigator>
      <last_name>Pavel Stodulka, Dr. med, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>June 13, 2014</study_first_submitted>
  <study_first_submitted_qc>June 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2014</study_first_posted>
  <last_update_submitted>April 23, 2015</last_update_submitted>
  <last_update_submitted_qc>April 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Astigmatism, arcuate incisions, astigmatic keratotomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astigmatism</mesh_term>
    <mesh_term>Surgical Wound</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

